In recent news, VK Paul, member, Health, Niti Aayog, said that the trial efficiency of the new Novavax vaccine bodes well for the country and that Serum Institute of India (SII) will be producing the vaccine in association with the US firm Novavax. Reportedly, the new vaccine has depicted 90% efficacy in trials conducted till date.
Pune-based Serum Institute has been engaged in carrying out bridging trials for the vaccine in India and is currently near completion. The positive news was shared by Paul at a ministry of health and family welfare (MoHFW) media briefing held earlier. According to trial data, the vaccine is safe and effective and it will be produced in large quantities, in the country itself. For the same, the Serum Institute has already completed the preparatory work.
News reports have quoted Stanley C Erck, President and Chief Executive Officer, Novavax saying that, “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection.”
In further good news, Paul mentioned that trial of the Novavax vaccine would soon be started in the pediatric population as the vaccine is considered safe for adults. Accordingly, the Serum Institute has committed to produce and provide 20 crore Novavax doses between the months of September and December this year.
News reports also state that vaccination has crossed the 26-crore milestone in India and this is likely to be further boosted by the influx of Novavax.
Credits : Times of India